Hims & Hers Health Inc. ($HIMS) Stock Forecast: Up 5.3% Today

What is Hims & Hers Health Inc.?

Hims & Hers Health, Inc. (HIMS) is a digital health company providing personalized healthcare solutions. The stock saw a significant bullish movement today.

Why is Hims & Hers Health Inc. going up?

HIMS stock is up 5.3% on Oct 24, 2025 14:00

• Despite a small price drop, HIMS ended the day on a high note, indicating a strong bullish trend.
• The company's focus on AI-driven personalized healthcare and recent substantial investments likely contributed to increased investor confidence in its growth potential.
• Although not immediately reflected in the stock price, the introduction of a women's health specialty highlights HIMS' dedication to expanding its offerings and customer base.
• With positive initial analyst coverage and favorable comparisons to other value stocks, HIMS appears to be attracting investor attention as a compelling investment opportunity.

HIMS Price Chart

HIMS Technical Analysis

HIMS News

Why Hims & Hers Health, Inc. ( HIMS ) Dipped More Than Broader Market Today

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $47.46, marking a -3.85% move from the previous day.

https://www.zacks.com/stock/news/2774583/why-hims-hers-health-inc-hims-dipped-more-than-broader-market-today

Hims & Hers Advances AI-Powered Personalized Digital Healthcare

HIMS accelerates AI-powered care with new tech leadership, personalized treatments and a major $870 million investment push.

https://www.zacks.com/stock/news/2774279/hims-hers-advances-ai-powered-personalized-digital-healthcare

HIMS Stock Declines Despite Launch of New Specialty in Women's Health

Hims & Hers debuts a new women's health specialty, targeting menopause care with personalized treatment plans.

https://www.zacks.com/stock/news/2773183/hims-stock-declines-despite-launch-of-new-specialty-in-womens-health

This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Hims & Hers Health ( NYSE:HIMS ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

https://www.benzinga.com/analyst-stock-ratings/initiation/25/10/48324870/this-acadia-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-t

OMCL or HIMS: Which Is the Better Value Stock Right Now?

OMCL vs. HIMS: Which Stock Is the Better Value Option?

https://www.zacks.com/stock/news/2771277/omcl-or-hims-which-is-the-better-value-stock-right-now

Trending Today

Bittensor ($TAO) Crypto Forecast: Up 5.2% Today

Hedera Hashgraph ($HBAR) Crypto Forecast: Up 5.0% Today

Soybeans ($SOY) Commodity Forecast: Down 0.4% Today

ZCash ($ZEC) Crypto Forecast: Up 11.6% Today

Duolingo Inc. ($DUOL) Stock Forecast: Down 6.9% Today

Centene Corporation ($CNC) Stock Forecast: Up 12.8% Today

American Electric Power Company Inc. ($AEP) Stock Forecast: Up 6.2% Today

DaVita Inc. ($DVA) Stock Forecast: Down 1.9% Today

Garmin Ltd. ($GRMN) Stock Forecast: Down 11.7% Today

Fiserv Inc. ($FI) Stock Forecast: Down 43.9% Today

Hims & Hers Health Inc. Price History

10.09.2025 - HIMS Stock was down 5.4%

• The bearish movement in HIMS stock today could be due to profit-taking by investors after a period of strong growth.
• Despite the expansion of its telehealth platform and international growth plans, investors may have been expecting even more significant developments or revenue projections.
• Market sentiment towards telehealth companies may have shifted, impacting HIMS stock negatively despite its positive news.

26.08.2025 - HIMS Stock was up 7.7%

• HIMS stock experienced a strong bullish movement despite closing at a lower price than the previous day.
• Investor interest in HIMS was potentially sparked by a comparison with Doximity, leading to the bullish trend.
• The slight decline in HIMS stock price may be attributed to profit-taking following a period of growth.
• Optimism among investors regarding HIMS's future earnings growth and platform expansion may be fueling the overall bullish sentiment.

24.09.2025 - HIMS Stock was up 5.3%

• Despite a small price drop, HIMS ended the day on a high note, indicating a strong bullish trend.
• The company's focus on AI-driven personalized healthcare and recent substantial investments likely contributed to increased investor confidence in its growth potential.
• Although not immediately reflected in the stock price, the introduction of a women's health specialty highlights HIMS' dedication to expanding its offerings and customer base.
• With positive initial analyst coverage and favorable comparisons to other value stocks, HIMS appears to be attracting investor attention as a compelling investment opportunity.

30.08.2025 - HIMS Stock was down 5.1%

• The release of the YieldMax HIMS Option Income Strategy ETF might have prompted heightened selling activity in HIMS shares, potentially due to investor interest shifting to this new ETF.
• A comparison of HIMS with Doximity in terms of earnings growth and platform expansion could have underscored areas where HIMS is trailing, sparking investor unease and contributing to the bearish trend.
• The more pronounced drop in HIMS compared to the wider market suggests specific company-related factors, such as performance metrics or market sentiment, might have played a role in the negative stock movement.

17.09.2025 - HIMS Stock was down 14.9%

• HIMS stock saw a significant drop after President Donald Trump's remarks about anticipated price decreases in popular weight-loss drugs. This development likely sparked investor concerns about HIMS's revenue and profitability.
• The company's recent expansions into men's health and hormone therapies, coupled with increasing costs and regulatory challenges, may have contributed to the negative sentiment surrounding HIMS stock.
• The downward trend in HIMS stock aligns with a broader pattern of investors reassessing the company's growth potential in the face of regulatory uncertainties and competition in the healthcare sector.

17.09.2025 - HIMS Stock was down 15.5%

• HIMS stock faced significant bearish movement, potentially due to recent statements by notable figures regarding price decreases for weight-loss medications. This may have negatively impacted the company's revenue forecasts.
• Despite HIMS' focus on improving healthcare access and its expansion into men's health and hormones through technology, concerns over escalating expenses and regulatory matters may have contributed to investor apprehension, resulting in the stock's decline.
• The -7.36% drop in HIMS stock price, surpassing the overall market's downturn, indicates that factors specific to the company, such as regulatory obstacles and cost escalations, are dampening investor trust and steering the downward trend.

03.09.2025 - HIMS Stock was down 5.0%

• The method of increasing health access through subscription revenues did not sway the stock's performance in a positive direction.
• Contrasts with other value stocks like OMCL prompted discussions on HIMS' valuation and future outlook.
• Market sentiment was pessimistic towards HIMS, with major investors showing a bearish outlook.
• The launch of a new ETF by YieldMax linked to HIMS did not notably boost the stock's performance.

15.09.2025 - HIMS Stock was up 6.5%

• The positive movement in HIMS stock today reflects the company's strategic expansion into men's health and hormones, which could attract new customers and boost revenue.
• Despite challenges such as regulations and costs, the market shows confidence in HIMS' future, particularly following its telehealth platform expansion.
• Investors see potential in HIMS due to its innovative telehealth services and commitment to increasing healthcare access through technology.
• The recent stock drop in HIMS may have been a momentary blip, likely more affected by general market trends than inherent issues with the company.

22.09.2025 - HIMS Stock was down 5.4%

• Despite the launch of a new specialty in women's health and elevating technology-driven healthcare accessibility, HIMS stock experienced a bearish movement.
• The negative market sentiment could be attributed to comments from President Donald Trump on the expected decrease in prices of weight-loss drugs, impacting investor confidence in HIMS.
• The initiation of coverage on a bullish note by analysts for ACADIA Pharmaceuticals and other companies might have shifted investor attention away from HIMS, contributing to the bearish movement.
• Investors comparing HIMS to other value stocks like OMCL might have chosen to reallocate their investments, leading to the decline in HIMS stock price.

22.09.2025 - HIMS Stock was down 6.8%

• Despite progress in AI-powered personalized healthcare and the launch of a new women's health specialty, HIMS stock declined, potentially influenced by market sentiment.
• An $870 million investment infusion and positive analyst coverage failed to counterbalance the impact of remarks made by President Trump regarding drug price reductions on HIMS stock.
• Comparing the stock with another for valuation purposes could have influenced investor choices, contributing to the downward movement.
• The bearish trend observed in HIMS stock today appears to be driven by a mix of factors, including external remarks impacting the healthcare industry and investor perceptions regarding the stock's value proposition.

14.09.2025 - HIMS Stock was down 5.3%

• HIMS stock price dropped by -7.36% from the previous day's close.
• Despite the company's efforts to expand its telehealth platform and enter international markets, market conditions or specific company events may have led to the negative investor response.
• The bearish movement might also be influenced by investors taking profits after a growth period or concerns regarding the company's future profitability.
• Investors should monitor HIMS closely for any developments to gauge the continuation of the bearish trend or potential recovery opportunities.

16.09.2025 - HIMS Stock was down 7.7%

• The recruitment of a new technology chief and the entry into men's health and hormone therapies were seen as positive developments for HIMS.
• However, worries about escalating expenses and regulatory obstacles could have influenced the stock's decline.
• The overall market downturn might have also impacted the decrease in HIMS stock value.
• Investors could be exercising caution regarding the company's capacity to overcome challenges and sustain its growth trajectory amidst growing costs and regulatory uncertainties.